5-氟尿嘧啶对改善晚期胃癌患者近期疗效及远期生存情况的影响研究

doi:10.3760/cma.j.issn.1007-1245.2023.24.023

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (24): 3638-3641.DOI: 10.3760/cma.j.issn.1007-1245.2023.24.023

5-氟尿嘧啶对改善晚期胃癌患者近期疗效及远期生存情况的影响研究

吴珊珊马文君

南阳市第一人民医院肿瘤二科，南阳　473000

收稿日期:2023-06-12 出版日期:2023-12-15 发布日期:2024-01-04
通讯作者: 吴珊珊，Email：wushanshantz@yeah.net
基金资助:
河南省科技攻关项目（212102310168）

5-fluorouracil in improvement of short-term efficacy and long-term survival of patients with advanced gastric cancer

Wu Shanshan, Ma Wenjun

Second Department of Oncology, Nanyang First People's Hospital, Nanyang 473000, China

Received:2023-06-12 Online:2023-12-15 Published:2024-01-04
Contact: Wu Shanshan, Email: wushanshantz@yeah.net
Supported by:
Problem-tackling Project of Science and Technology in Henan (212102310168)

摘要/Abstract

摘要：

目的　观察5-氟尿嘧啶（5-FU）对改善晚期胃癌患者近期疗效及远期生存情况的影响。方法　选取南阳市第一人民医院2020年1月至2022年5月收治的98例晚期胃癌患者进行随机对照试验，以随机数字表法对入组患者进行分组，分别列为常规组（48例）和试验组（50例）。常规组中男25例，女23例，年龄43～77（60.22±5.13）岁，实施XELOX标准化疗；试验组中男29例，女21例，年龄45～75（60.33±5.21）岁，采用含5-FU的一线化疗，两组患者均统一治疗4个周期后评估疗效。比较两组患者的近期疗效，随访1年后的远期生存周期、生存质量及化疗相关不良反应发生情况。统计学方法采用t检验、χ²检验。结果　试验组的病灶客观缓解率（ORR）、疾病控制率（DCR）均高于常规组［76.00%（38/50）比62.45%（30/48）、82.00%（41/50）比66.67%（32/48）］，差异均有统计学意义（χ²=4.309、6.159，均P<0.05）。试验组的中位无进展生存期（PFS）、中位总生存期（OS）均高于常规组［（9.25±2.11）个月比（7.24±2.25）个月、（10.24±2.21）个月比（8.01±2.18）个月］，差异均有统计学意义（t=3.060、2.306，均P<0.05）。试验组的癌症患者生命质量测定量表（FACT-G）中生理状况、社会家庭状况、情感状况、功能状况评分均高于常规组［（22.41±5.13）分比（19.33±5.16）分、（22.25±5.23）分比（19.45±5.23）分、（19.47±5.18）分比（16.23±5.35）分、（22.36±5.24）分比（19.31±5.17）分］，差异均有统计学意义（t=2.963、2.649、3.046、2.899，均P<0.05）。随访期间，试验组的化疗相关不良反应发生率为24.00%（12/50），低于常规组［37.50%（18/48）］，差异有统计学意义（χ²=4.279，P<0.05）。结论　与标准化疗方案相比，应用5-FU+奥沙利铂化疗能改善晚期胃癌患者的近期疗效，对延长患者生存周期、改善生存质量均有积极意义，安全性更高。

关键词:

晚期胃癌, 5-氟尿嘧啶, 一线化疗, 近期疗效, 生存情况

Abstract:

Objective　Observe To observe effect of 5-FU on improving the short-term efficacy and long-term survival of patients with advanced gastric cancer. Methods　Ninety-eight patients with advanced gastric cancer treated at Nanyang First People's Hospital from January 2020 to May 2022 were selected for the randomized controlled trial, and were divided into a conventional group (48 cases) and an experimental group (50 cases) by the random number table method. There were 25 males and 23 females in the conventional group; they were 43-77 (60.22±5.13) years old. There were 29 males and 21 females in the experimental group; they were 45-75 (60.33±5.21) years old. The conventional group took XELOX standard chemotherapy, and the experimental group first-line chemotherapy containing 5-FU. Both groups were treated for 4 weeks. The short-term efficacies, long-term survival cycles and quality of life after one-year follow up, and incidences of chemotherapy related adverse reactions were compared between the two groups. t and χ² tests were applied. Results　The objective relieved rate and disease controlled rate in the experimental group were higher than those in the control group [76.00% (38/50) vs. 62.45% (30/48) and 82.00% (41/50) vs. 66.67% (32/48)], with statistical differences (χ²=4.309 and 6.159; both P<0.05). The median PFS and OS in the experimental group were higher than those in the control group [(9.25±2.11) months vs. (7.24±2.25)months and (10.24±2.21) months vs. (8.01±2.18) months], with statistical differences (t=3.060 and 2.306; both P<0.05). The scores of physical status, social and family status, emotion status, and functional status of Functional Assessment of Cancer Therapy-General (FACT-G) in the experimental group were higher than those in the control group [(22.41±5.13) vs. (19.33±5.16), (22.25±5.23) vs. (19.45±5.23), (19.47±5.18) vs. (16.23±5.35), and (22.36±5.24) vs. (19.31±5.17)], with statistical differences (t=2.963, 2.649, 3.046, and 2.899; all P<0.05). During the follow up, the incidence of chemotherapy related adverse reactions in the experimental group was lower than that in the conventional group [24.00% (12/50) vs. 37.50% (18/48)], with a statistical difference (χ²=4.279, P<0.05). Conclusion　Compared with the standard chemotherapy, 5-FU assisted first-line chemotherapy can improve the short-term efficacy of patients with advanced gastric cancer, and has positive significance in prolonging the patients' life cycle and improving their quality of life, and is safe.

Key words:

Advanced gastric cancer, 5-fluorouracil, First line chemotherapy, Short efficacy, Survival situation

吴珊珊马文君.

5-氟尿嘧啶对改善晚期胃癌患者近期疗效及远期生存情况的影响研究 [J]. 国际医药卫生导报, 2023, 29(24): 3638-3641.

Wu Shanshan, Ma Wenjun.

5-fluorouracil in improvement of short-term efficacy and long-term survival of patients with advanced gastric cancer [J]. International Medicine and Health Guidance News, 2023, 29(24): 3638-3641.

参考文献

[1] Machlowska J, Baj J, Sitarz M, et al. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies[J]. Int J Mol Sci,2020,21(11):4012.DOI: 10.3390/ijms21114012.
[2] 赵倩,杨振威,赵艳,等. 体检人群胃镜检查发现胃癌及胃癌前疾病结果分析[J]. 临床消化病杂志,2022,34(1):26-30. DOI:10.3870/lcxh.j.issn.1005-541X.2022.01.006.
[3] 林鹏航,林春霖,王琴,等. 胃癌D2根治术后短期并发症对患者远期生存率的影响[J]. 肿瘤防治研究,2021,48(6):625-630. DOI:10.3971/j.issn.1000-8578.2021.20.1390.
[4] 蒋祈,张鹏,陶凯雄. 美国国立综合癌症网络临床实践指南:胃癌(2022.V2)更新解读[J]. 临床外科杂志,2023,31(1):21-23. DOI:10.3969/j.issn.1005-6483.2023.01.007.
[5] 郭洪波,范招银,朱珠,等. 奥沙利铂联合氟尿嘧啶治疗晚期胃癌的近期疗效及预后[J]. 临床合理用药杂志,2022,15(35):80-82. DOI:10.15887/j.cnki.13-1389/r.2022.35.025.
[6] 张静,谭小平,周红,等. 奥沙利铂联合氟尿嘧啶治疗老年晚期胃癌疗效及不良反应[J]. 中国老年学杂志,2021,41(17):3649-3651. DOI:10.3969/j.issn.1005-9202.2021.17.006.
[7] 中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会胃癌临床诊疗指南(2021版)[J]. 中华医学杂志,2022,102(16):1169-1189. DOI:10.3760/cma.j.cn112137- 20220127-00197.
[8] 宋刚,沈琳,龚继芳. 真实世界晚期胃癌一线化疗模式多维评估[J/CD]. 肿瘤综合治疗电子杂志,2021,7(2):33-38. DOI:10.12151/JMCM.2021.02-05.
[9] Sjoquist KM, Martin A, Pavlakis N,et al. Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer[J]. J Cancer Res Clin Oncol, 2023,149(8):4959-4965.DOI: 10.1007/s00432- 022-04404-4.
[10] MA Y,ZONG H,WANG J,et al. Efficacy and safety of apatinib in treatment of gastric cancer: A real-world study[J].JCO,2021,39(3):182-182.DOI: 10.1200/JCO.2021.39.3_suppl.182.
[11] 张丽丽,韩明强,崔占斌,等. 中文版FACT-G量表在肿瘤患者生命质量评价中的适用性研究[J]. 中国卫生统计,2022,39(2):243-245. DOI:10.3969/j.issn.1002-3674.2022. 02.019.
[12] Oh DY, Lee SH, Han SW, et al. Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors[J]. Cancer Res Treat, 2015,47(4):607-615.DOI: 10.4143/crt.2014.249.
[13] 孙婷,柯希权,王启之. 幽门螺杆菌感染相关异时性胃癌的研究进展[J]. 国际消化病杂志,2022,42(3):159-162. DOI:10.3969/j.issn.1673-534X.2022.03.005.
[14] 梅刚. 胃癌患者腹腔镜辅助全胃切除手术治疗的有效性及对患者预后的影响[J]. 实用癌症杂志,2021,36(2):316-318. DOI:10.3969/j.issn.1001-5930.2021.02.036.
[15] 武四化,刘胜海,刘澎涛,等. S-1单药和卡培他滨联合奥沙利铂两种化疗方案对Ⅱ期胃癌术后患者的有效性和安全性分析[J]. 湖南师范大学学报(医学版),2022,19(2):180-183. DOI:10.3969/j.issn.1673-016X.2022.02.050.
[16] 赵淑霞,肖琼. XELOX与FOLFOX4新辅助化疗方案对进展期胃癌根治术疗效的对比研究[J]. 河南外科学杂志,2022,28(5):39-41.
[17] 田艺,张佳丽. 5-氟尿嘧啶促进HPV阳性宫颈癌细胞凋亡的Wnt/β-catenin信号通路机制研究[J]. 医学临床研究,2022,39(7):1022-1025. DOI:10.3969/j.issn.1671-7171. 2022.07.017.
[18] 成兴真,杨芳,王杨,等. 白蛋白紫杉醇与五氟尿嘧啶联合用药对人胃癌细胞增殖及周期的影响[J]. 贵州医科大学学报,2021,46(11):1289-1293,1300. DOI:10.19367/j.cnki.2096-8388.2021.11.008.
[19] 郑文金. 奥沙利铂联合氟尿嘧啶治疗晚期胃癌的近期疗效及预后[J]. 临床合理用药杂志,2021,14(8):16-18. DOI:10.15887/j.cnki.13-1389/r.2021.08.006.
[20] Deng R, Shi L, Zhu W, et al. Pharmacokinetics-based dose management of 5-fluorouracil clinical research in advanced colorectal cancer treatment[J]. Mini Rev Med Chem, 2020,20(2):161-167. DOI: 10.2174/1389557519666191011154923.

5-氟尿嘧啶对改善晚期胃癌患者近期疗效及远期生存情况的影响研究

5-fluorouracil in improvement of short-term efficacy and long-term survival of patients with advanced gastric cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

[1]	窦东锋刘洪光张丽芬. 单硝酸异山梨酯联合培哚普利叔丁胺治疗老年慢性心力衰竭患者的疗效 [J]. 国际医药卫生导报, 2023, 29(9): 1276-1280.
[2]	沙莎杨秋敏. 不同PD-1抑制剂治疗胃肠道肿瘤的临床效果 [J]. 国际医药卫生导报, 2023, 29(13): 1828-1831.